Reference entry

PT-141 (Bremelanotide)

Melanocortin Receptor Agonist · Sexual Dysfunction Treatment

Overview

FDA-approved melanocortin receptor agonist for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Works centrally in the nervous system to trigger sexual arousal pathways independent of vascular mechanisms, unlike traditional ED medications.

Selectively activates melanocortin receptors (MC3R/MC4R) in the central nervous system, triggering sexual arousal pathways independent of peripheral vascular mechanisms. Works within 45 minutes with effects lasting 6-12 hours.

FDA-approved for treatment of HSDD in premenopausal women.

Effective in men including PDE5 inhibitor-resistant cases via CNS pathways.

Enhances sexual arousal and desire in women.

Reduces distress related to low sexual desire.

Mechanism

FDA-approved for treatment of HSDD in premenopausal women.

Research areas

FDA-approved melanocortin receptor agonist for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Works centrally in the nervous system to trigger sexual arousal pathways independent of vascular mechanisms, unlike traditional ED medications.
Selectively activates melanocortin receptors (MC3R/MC4R) in the central nervous system, triggering sexual arousal pathways independent of peripheral vascular mechanisms. Works within 45 minutes with effects lasting 6-12 hours.
FDA-approved for treatment of HSDD in premenopausal women.
Effective in men including PDE5 inhibitor-resistant cases via CNS pathways.
Enhances sexual arousal and desire in women.
Reduces distress related to low sexual desire.
Enhanced satisfaction reported in clinical trials.

Research notes

Nausea (40%)
Flushing (20%)
Headache (11%)
Injection site reactions
Severe or persistent nausea/vomiting
Significant blood pressure drop or dizziness
Chest pain or irregular heartbeat
Severe headache or vision changes
Prolonged erection exceeding 4 hours
Uncontrolled hypertension
Cardiovascular disease
Use of nitrate medications
Pregnancy or breastfeeding

AXIOM catalogue

PT-141 — research-use catalogue record with strengths and available batch details where listed.

References

FAQs

How is PT-141 different from Viagra if both treat erectile dysfunction?

Completely different mechanisms. Viagra (sildenafil) works peripherally by dilating blood vessels in the penis (PDE5 inhibition). PT-141 works centrally in the brain via melanocortin receptors to trigger sexual desire and arousal independent of blood flow. PT-141 can even work in PDE5 inhibitor-resistant cases because it bypasses the vascular system entirely.

Why does PT-141 cause nausea in 40% of people?

PT-141 activates melanocortin receptors broadly in the brain, not just sexual arousal centers. Off-target activation in nausea-control areas is a known side effect. Taking an anti-nausea medication 30 minutes before PT-141 (as recommended in the file) significantly reduces this. Many users find pre-medication worthwhile for the benefit.

Can women use PT-141, or is it only for men?

Women can use it. PT-141 is FDA-approved for female HSDD (hypoactive sexual desire disorder) at 1.75mg. Men use 1-2mg for ED. The mechanism is identical—melanocortin receptor activation increases sexual arousal in both sexes. It's one of the few sexual enhancement drugs with proven efficacy specifically in women.

Is PT-141 safe if I have high blood pressure?

No. PT-141 raises blood pressure and causes flushing. The file lists uncontrolled hypertension as a contraindication. Monitor your BP closely if you have hypertension, and avoid combining with blood pressure-lowering medications. Nitrates are specifically contraindicated due to severe hypotension risk.